Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 4/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14827593 | 0.89 | FABP7 (0.55) | FABP7FABP5TSHRALDH1A1HTR2C | |
| SCHEMBL14828644 | 0.87 | FABP7 (0.46) | FABP7FABP5TSHRALDH1A1HTR2C | |
| SCHEMBL14827592 | 0.87 | ALDH1A1 (0.48) | FABP7FABP5TSHRALDH1A1HTR2C | |
| SCHEMBL14827594 | 0.87 | ALDH1A1 (0.48) | FABP7FABP5TSHRALDH1A1HTR2C | |
| SCHEMBL13197262 | 0.81 | FABP7 (0.54) | FABP7FABP5TSHRALDH1A1HTR2C | |
| SCHEMBL13198696 | 0.81 | CPB1 (0.43) | FABP7FABP5TSHRCA1CA2 | |
| SCHEMBL10119904 | 0.81 | CPB1 (0.43) | FABP7FABP5TSHRCA1CA2 | |
| SCHEMBL31145528 | 0.79 | FABP7 (0.61) | FABP7FABP5TSHRALDH1A1HTR2C | |
| SCHEMBL10119908 | 0.76 | ALDH1A1 (0.48) | FABP7FABP5TSHRALDH1A1CA1 | |
| SCHEMBL1838935 | 0.76 | ALDH1A1 (0.55) | FABP7FABP5TSHRALDH1A1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | SBDS, NCL, INTS6 | FABP7 4149/4885FABP5 3342/4885TSHR 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.